Microglia are not innocent bystanders in neurodegeneration—they are active drivers of disease

We have treated neuroinflammation as a side effect of neurodegeneration. The evidence suggests it is a primary driver. In ALS, microglial activation in the corticospinal tract correlates directly with disease progression severity. In Alzheimer disease and Parkinson disease, activated microglia cluster around pathology and release inflammatory mediators that accelerate neuron death. The question is not whether neuroinflammation matters—it is whether we can target it therapeutically without compromising the immune surveillance microglia provide.